Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have rapidly transformed the management of type 2 diabetes and obesity. While their cardiovascular and metabolic benefits are well established, their effects on the gastrointestinal (GI) system are often underappreciated in routine care. GLP-1 RAs modulate appetite, gastric emptying, and intestinal motility, making the GI tract both the therapeutic target and the primary site of adverse events.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Bianca
Contact Bianca, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack